"Antiviral Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
| Descriptor ID |
D000998
|
| MeSH Number(s) |
D27.505.954.122.388
|
| Concept/Terms |
Antiviral Agents- Antiviral Agents
- Agents, Antiviral
- Antivirals
- Antiviral Drugs
- Drugs, Antiviral
|
Below are MeSH descriptors whose meaning is more general than "Antiviral Agents".
Below are MeSH descriptors whose meaning is more specific than "Antiviral Agents".
This graph shows the total number of publications written about "Antiviral Agents" by people in this website by year, and whether "Antiviral Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 3 | 5 |
| 1997 | 1 | 1 | 2 |
| 1998 | 3 | 4 | 7 |
| 1999 | 4 | 1 | 5 |
| 2000 | 1 | 8 | 9 |
| 2001 | 7 | 2 | 9 |
| 2002 | 5 | 6 | 11 |
| 2003 | 8 | 6 | 14 |
| 2004 | 8 | 5 | 13 |
| 2005 | 8 | 6 | 14 |
| 2006 | 5 | 9 | 14 |
| 2007 | 9 | 4 | 13 |
| 2008 | 8 | 2 | 10 |
| 2009 | 12 | 9 | 21 |
| 2010 | 11 | 4 | 15 |
| 2011 | 14 | 12 | 26 |
| 2012 | 8 | 6 | 14 |
| 2013 | 9 | 5 | 14 |
| 2014 | 13 | 2 | 15 |
| 2015 | 21 | 8 | 29 |
| 2016 | 10 | 13 | 23 |
| 2017 | 25 | 9 | 34 |
| 2018 | 22 | 6 | 28 |
| 2019 | 19 | 8 | 27 |
| 2020 | 18 | 15 | 33 |
| 2021 | 18 | 15 | 33 |
| 2022 | 4 | 30 | 34 |
| 2023 | 6 | 22 | 28 |
| 2024 | 12 | 8 | 20 |
| 2025 | 16 | 3 | 19 |
| 2026 | 4 | 1 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antiviral Agents" by people in Profiles.
-
Economic and humanistic burden of chronic liver diseases in the United States. Expert Rev Pharmacoecon Outcomes Res. 2026 Mar; 26(3):379-387.
-
Impact of Hepatitis C screening and treatment among incarcerated populations in Alberta, Canada on population-level Hepatitis C elimination efforts. Int J Drug Policy. 2026 Apr; 150:105201.
-
Influenza Antiviral Use in Hospitalized Children Before and During the COVID-19 Pandemic. Pediatrics. 2026 Feb 01; 157(2).
-
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab. Clin Infect Dis. 2026 Jan 16; 81(Supplement_3):i13-i16.
-
2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis. Clin Infect Dis. 2026 Jan 16; 81(Supplement_3):i6-i12.
-
Identification of affinity-optimized peptide binders of a viral protease for chemical genetic applications. Bioorg Med Chem Lett. 2026 Feb 01; 131:130463.
-
Retreatment or prolonged antiviral therapy in severe acute respiratory syndrome Coronavirus-2 infection among immunocompromised patients during 2022-2023: A nationwide claims-based cohort study in Japan. J Infect Chemother. 2025 Nov; 31(11):102830.
-
Antiviral Use Among Children Hospitalized With Laboratory-Confirmed Influenza Illness: A Prospective, Multicenter Surveillance Study. Clin Infect Dis. 2025 Oct 06; 81(3):623-633.
-
Effect of sustained virologic response on liver-related mortality among individuals living with hepatitis C by treatment era: A population-based retrospective cohort study. PLoS One. 2025; 20(10):e0333584.
-
Clinician Preferences for Oseltamivir Use in Children With Influenza in the Outpatient Setting. Pediatrics. 2025 Sep 01; 156(3).